Chen Jie1, Wang Xuan2, Han-Dong Feng3, Ding-Mao Hua3, Wang Bo3, Sun Fei3, Zhang Hao3. 1. Department of Neurosurgery, XuZhou Central Hospital, Xuzhou, China. SYSYS606@163.COM. 2. Xuzhou First People's Hospital, The Affiliated Hospital of China University of Mining and Technology, Xuzhou, China. 3. Department of Neurosurgery, XuZhou Central Hospital, Xuzhou, China.
Abstract
BACKGROUND: AdipoR2, which belongs to the seven-transmembrane-domain receptor family, has been shown to play an important role in the development of human tumours, but the underlying mechanisms are poorly understood. In this study, we found that AdipoR2 expression correlates with glioma grade. In addition, we also investigated the mechanisms behind the antiproliferative effects of AdipoR2 in U251 cells (a human glioma cell line) using colony formation and WST-8 growth assays. METHODS: The U251 cell line was cultured in vitro. Western blotting was used to detect the expression of relevant proteins. Quantitative RT-PCR was used to detect AdipoR1 and AdipoR2 expression. Flow cytometry was used to detect cell cycle assay results. The gene expression profiles of glioma samples from the CGGA database were analysed by MATLAB and GSEA software. RESULTS: The AMPK/mTOR pathway plays a central role in the regulation of cell proliferation, differentiation and migration and may promote tumorigenesis. Therefore, we can control cancer progression by modulating the AMPK/mTOR pathway. However, there is no information on the relationship between AdipoR and AMPK/mTOR in central nervous system tumours such as GBM. In this study. We found 648 upregulated genes and 436 downregulated genes correlated with AdipoR2 expression in 158 glioma samples. GSEA suggested that AdipoR2 is a cell cycle-associated gene. The results of the flow cytometry analysis indicated that AdipoR2 induced G0/G1 cell cycle arrest in U251 cells. Furthermore, we identified the AMPK/mTOR signalling axis to be involved in AdipoR2-induced cell cycle arrest. CONCLUSIONS: Our results suggest that AdipoR2 may represent a novel endogenous negative regulator of GBM cell proliferation. These findings also suggest that AdipoR2 may be a promising therapeutic target in GBM patients.
BACKGROUND:AdipoR2, which belongs to the seven-transmembrane-domain receptor family, has been shown to play an important role in the development of humantumours, but the underlying mechanisms are poorly understood. In this study, we found that AdipoR2 expression correlates with glioma grade. In addition, we also investigated the mechanisms behind the antiproliferative effects of AdipoR2 in U251 cells (a humanglioma cell line) using colony formation and WST-8 growth assays. METHODS: The U251 cell line was cultured in vitro. Western blotting was used to detect the expression of relevant proteins. Quantitative RT-PCR was used to detect AdipoR1 and AdipoR2 expression. Flow cytometry was used to detect cell cycle assay results. The gene expression profiles of glioma samples from the CGGA database were analysed by MATLAB and GSEA software. RESULTS: The AMPK/mTOR pathway plays a central role in the regulation of cell proliferation, differentiation and migration and may promote tumorigenesis. Therefore, we can control cancer progression by modulating the AMPK/mTOR pathway. However, there is no information on the relationship between AdipoR and AMPK/mTOR in central nervous system tumours such as GBM. In this study. We found 648 upregulated genes and 436 downregulated genes correlated with AdipoR2 expression in 158 glioma samples. GSEA suggested that AdipoR2 is a cell cycle-associated gene. The results of the flow cytometry analysis indicated that AdipoR2 induced G0/G1 cell cycle arrest in U251 cells. Furthermore, we identified the AMPK/mTOR signalling axis to be involved in AdipoR2-induced cell cycle arrest. CONCLUSIONS: Our results suggest that AdipoR2 may represent a novel endogenous negative regulator of GBM cell proliferation. These findings also suggest that AdipoR2 may be a promising therapeutic target in GBM patients.
Authors: Jennifer R Rider; Michelangelo Fiorentino; Rachel Kelly; Travis Gerke; Kristina Jordahl; Jennifer A Sinnott; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci; Stephen Finn Journal: Carcinogenesis Date: 2015-04-11 Impact factor: 4.944
Authors: Diane C Fingar; Celeste J Richardson; Andrew R Tee; Lynn Cheatham; Christina Tsou; John Blenis Journal: Mol Cell Biol Date: 2004-01 Impact factor: 4.272
Authors: Fabiola Marín-Aguilar; Luis E Pavillard; Francesca Giampieri; Pedro Bullón; Mario D Cordero Journal: Int J Mol Sci Date: 2017-01-29 Impact factor: 5.923